<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-144
Date of Submission: 2024-10-11

This report was submitted by a Other Healthcare Professional from Edwards-Douglas Medical Center concerning patient ANON-PX-3859. The subject is a 46-year-old female with a significant medical history including hypertension, asthma, anxiety, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Intravenous route at a dosage of 421mg, initiated on 2024-08-28 for Hypercholesterolemia and discontinued on 2024-10-05.

On approximately 2024-09-26, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Stevens-Johnson syndrome, Nausea. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Stevens-Johnson syndrome was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed anyone and advised environmental. The current patient status regarding this symptom is 'Not Recovered'. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Possible resource head common drop. Include common indicate itself police opportunity off.</data>
report_id: ADR-2024-144
report_date: '2024-10-11'
patient_details:
  patient_id: ANON-PX-3859
  gender: Female
  relevant_history:
  - hypertension
  - asthma
  - anxiety
  - coronary artery disease
  age_at_reaction: 46
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 421mg
  route_of_administration: Intravenous
  start_date: '2024-08-28'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
  end_date: '2024-10-05'
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2024-09-26'
  severity: Mild
  outcome: Recovered
  intervention_required: false
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2024-09-26'
  severity: Life-threatening
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed anyone and advised environmental.
- symptom_name: Nausea
  onset_date: '2024-09-26'
  severity: Life-threatening
  outcome: Fatal
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Negative dechallenge
reporting_facility: Edwards-Douglas Medical Center
reporter_type: Other Healthcare Professional
notes: Possible resource head common drop. Include common indicate itself police opportunity
  off.
